The power of SS-31 & MOTS-c to restore kidney health is one of the most exciting peptide therapies that self-advocates are employing these days. The ramifications are massive on both a health and .gov debt scale. I cannot pound this drum loudly enough.

⬇️Reversing Renal Failure⬆️ 6-7% of Medicare cost and 1% of the entire federal budget is consumed by End Stage Renal Disease (ESRD) patients. I believe many patients' slide into ESRD can be reversed given the proper peptide therapy and hopefully I can prove it. Kidney failure is caused by four issues: diabetes, hypertension, autoimmune dysfunction, or acute injury. Hypertension is often associated with obesity and diabetes, so we are going to focus our efforts there. The stack I'm proposing has shown promise in reversing stage 3 chronic kidney disease (CKD) back to normal function in Australia. Once someone reaches stage 4 it's far more difficult to revert back to normal. I've added two other compounds I believe will increase the efficacy of the protocol. The Protocol & Why 1. MOTS-c (5mg twice/wk for 6wks)- CKD patients have reduced expression of MOTS-c and increased mitochondrial dysfunction.¹ MOTS-c's main mechanism of action is to activate the AMPK pathway leading to increased energy production, glucose uptake, enhancing insulin sensitivity, and most importantly reducing high glucose states. It's a systemic anti-inflammatory reducing oxidative stress that causes cell apoptosis and fibrous of the kidneys.¹ 2. SS-31 (5mg ED for 6 wks) The action isn't well understood, but it stabilizes the mitochondrial inner membrane where oxygen and electrons are exchanged and ATP is produced. SS-31 does not affect healthy mitochondria. It instead goes to damaged or weak areas. Protecting against reactive oxygen species leads to less peroxidation that damage mitochondria and causes fibrous of the kidneys.² 3. SLU-PP-332 (750mcg ED for 8wks) "The mechanism of action of SLU-PP-332 is to activate ERRs, leading to increased energy expenditure, fatty acid oxidation, and decreased fat mass accumulation.³" ERR agonist also reverse mitochondrial dysfunction and inflammation in ageing kidneys.⁴ Weight loss followed by administration of the compound would improve metabolic syndrome, type 2 diabetes, thus implying kidney protective efficacy. This is a new compound and although no side effects were noted in studies implications of long term use are not yet known. 4. Retatrutide (titration to 2-5mg/wk) Aside from the obvious weight loss which directly effects kidney function. This compound improved renal function and suppressed pro-inflammatory cytokines and pro-fibrotic factors in the kidneys.⁵ I truly believe this stack would reduce instances of CKD becoming ERSD. It would keep patients out of in-center dialysis treatment, which is an absolute nightmare. Not only that, but the reduction to the federal budget would be significant. Many birds. One stack.